Abstract: A sensor package includes a substrate, a light sensor disposed on the substrate, at least one optical filter disposed on the light sensor, and an optical functional layer that is light-permeable, is disposed on the substrate, covers the light sensor and the optical filter, and includes multiple light-scattering particles. The light sensor has a light receiving region, and receives light through the light receiving region. The optical filter covers the light receiving region. When the light passes through the optical filter within an incident angle range and is received by the light receiving region, the light sensor responds to a wavelength range of the light, and a response spectrum is obtained. Within the incident angle range, an absolute value of an offset measured at a crest of a waveform of the response spectrum is less than or equal to 10 nm. An electronic device is also provided.

Abstract: Described herein are methods for purifying I?Ip from a biological material using an endotoxin-binding agent. The method involves applying the biological material containing the I?Ip to an endotoxin-binding agent, discarding the flow through, applying a wash buffer(s), and eluting the I?Ip from the endotoxin-binding agent.

Abstract: The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-alpha inhibitor proteins (I?Ips), including, e.g., inter-alpha inhibitor (I?I) and/or pre-alpha inhibitor (P?I).

Abstract: Described herein are methods for quantifying IAIP levels in a sample.

Abstract: A device of a data testing environment including a node configured to connect the device to a tester; one or more processors configured to receive from the node an electrical signal alternating between at least a first state and a second state, the first state representing a data transmission trigger and the second state representing a data transmission opportunity; determine a timing of the data transmission opportunity based on the received electrical signal; and send data to the node during the data transmission opportunity in response to receiving the data transmission trigger.

Abstract: According to various aspects, a device is provided. The device is configured to receive a signal, the signal being configured to provide power and data to the device. The device includes: a charge storage element configured to be charged by the power provided by the received signal; and a charging control circuit configured to control a charging of the charge storage element by the power provided by the received signal, based on the data provided by the received signal.

Abstract: Described herein are methods for quantifying IAIP levels in a sample.

Abstract: Featured are a foodstuff containing an inter-alpha inhibitor protein (l?lp) (e.g., l?l, P?l, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof), methods of preparing a food-stuff containing an l?lp, and methods of treating and/or reducing the likelihood of developing a disease or condition (e.g., a disease or condition characterized by inflammation and/or low levels of an l?lp) in a subject in need thereof by administering a composition or a foodstuff containing an l?lp. Also featured are methods of purifying an l?lp (e.g., l?l, P?l, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof) from milk.

Abstract: The present invention provides a method for the prognosis of overall survival, cancer recurrence or response to treatment for a patient suffering from cancer, the method comprising: (a) examining a sample from the patient to determine whether the patient is human epidermal growth factor receptor 2 (HER2) positive or negative; and (b) measuring WW domain-binding protein 2 (WBP2) levels in the patient's sample, wherein a result in step (a) and a result in step (b) provides a prognosis of overall survival, cancer recurrence or response to treatment for the patient. The present invention also provides a kit carrying out the method of the present invention.

Abstract: A device of a data testing environment including a node configured to connect the device to a tester; one or more processors configured to receive from the node an electrical signal alternating between at least a first state and a second state, the first state representing a data transmission trigger and the second state representing a data transmission opportunity; determine a timing of the data transmission opportunity based on the received electrical signal; and send data to the node during the data transmission opportunity in response to receiving the data transmission trigger.

Abstract: Described herein are methods for quantifying lAIP levels in a sample (e.g., from a subject) using lAIP ligand-based assays. Also disclosed are methods for measuring lAIP-IAIP ligand complexes, and methods of evaluating, monitoring, and treating subjects using the aforementioned lAIP quantification methods.

Abstract: The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-alpha inhibitor proteins (lalps), including, e.g., inter-alpha inhibitor (lal) and/or pre-alpha inhibitor (Pal).

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The present invention provides a method for the prognosis of overall survival, cancer recurrence or response to treatment for a patient suffering from cancer, the method comprising: (a) examining a sample from the patient to determine whether the patient is human epidermal growth factor receptor 2 (HER2) positive or negative; and (b) measuring WW domain-binding protein 2 (WBP2) levels in the patient's sample, wherein a result in step (a) and a result in step (b) provides a prognosis of overall survival, cancer recurrence or response to treatment for the patient. The present invention also provides a kit carrying out the method of the present invention.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: The invention relates to Inter-alpha inhibitor proteins (I?Ip). The invention further relates to processes for purification of I?Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.